Intrabronchial surfactant application in cases of inhalation injury: first results from patients with severe burns and ARDS.
Damage to the respiratory tract caused by inhalation of toxic products of combustion with subsequent development of an acute respiratory distress syndrome (ARDS) is one of the main causes of death in burn patients. Treatment with an exogenous surfactant is a therapeutic option for which there has previously been no empirical data. We report on four severely burned patients with deep partial thickness and full thickness burns of between 40 and 70 per cent body surface area (BSA), and with inhalation injury complicated by ARDS. These patients were treated once or more than once with bovine surfactant replacement (Alveofact). In addition to biophysical and biochemical analysis, the influence of this substance on oxygenation and lung function were evaluated. After the limits of mechanical ventilation had been reached, bronchoscopic intrabronchial administration of surfactant was followed by temporarily improved gas exchange with an increase in arterial O2 partial pressure (PaO2), accompanied by a reduction in inspiratory O2 concentration (FiO2), and also improved lung compliance. All the patients survived in spite of an initially unfavourable prognosis. Replacement of exogenous surfactant in the treatment of inhalation traumatized severe burn patients with ARDS appears to show considerable promise as an approach to improving the survival chances of these high-risk patients.
Pallua
N
N
Clinic for Plastic, and Reconstructive Surgery, Burn Centre at University Hospital RTWH Aachen, Germany.
Warbanow
K
K
Noah
E M
EM
Machens
H G
HG
Poets
C
C
Bernhard
W
W
Berger
A
A
D000293:Adolescent; D000328:Adult; D001980:Bronchi; D002059:Burns, Inhalation / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007322:Instillation, Drug; D008297:Male; D008875:Middle Aged; D011663:Pulmonary Surfactants / Q000008:administration & dosage* / Q000627:therapeutic use; D012128:Respiratory Distress Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012129:Respiratory Function Tests; D012189:Retrospective Studies
D011663:Pulmonary Surfactants